YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
A study suggests high borrow costs are a good indicator that a stock will lag the broader market. - Getty Images/iStock Certain stocks are such poor bets that they are likely to lose ground even in bull markets. These "loser" stocks are on…
The liver cirrhosis market is expected to witness steady growth over the coming years, driven by the rising prevalence of chronic liver diseases, including hepatitis B, hepatitis C, alcohol-associated liver disease, and MASLD. In addition,…
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga., Aug. 04, 2026 (GLO…
(RTTNews) - Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder In…
(RTTNews) - Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in a…
Galectin Therapeutics GALT shares surged 11.4% on Tuesday after the company announced it had reached alignment with the FDA on key elements of the late-stage development program for belapectin, a galectin-3 inhibitor and its only clinical-…
(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and…
(RTTNews) - Galectin Therapeutics Inc. (GALT), a clinical-stage biotechnology company, announced that it reached alignment with the U.S. Food and Drug Administration during a recent in-person Type C meeting on the primary endpoint and regu…
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and fi…
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such investors are advised to contact Danielle Peyton at n…
(RTTNews) - Galectin Therapeutics Inc. (GALT) Friday announced that the U.S. FDA has provided written feedback on its development program for Belapectin, the company's investigational galectin-3 inhibitor for patients with MASH cirrhosis a…
(RTTNews) - Several small-cap biotech and healthcare names posted notable gains in Thursday's after-hours trading session, with investors reacting to recent corporate updates and clinical milestones. Inspira Technologies Oxy B.H.N. Ltd. (I…
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three…
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Galectin Therapeutics Inc. is one of them. Galectin Therapeutics Inc. (NASDAQ:GALT) is a biopharmaceutical company developing therapies t…
(RTTNews) - Several biotech stocks made sharp moves in after-hours trading on Thursday, September 11, 2025, driven by clinical updates, strategic pivots, and rebranding efforts. Here's a quick look at what sparked the action. Modular Medic…
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wai…
Director Kevin D Freeman acquired 5,000 shares of GALECTIN THERAPEUTICS INC (NASDAQ:GALT) on July 17, 2025, at a price of $2.899 per share, for a total transaction value of $14,495. The purchase comes amid strong momentum, with the stock u…
NORCROSS, Ga. - Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotech company with a market capitalization of $132 million and currently trading at $2.09, has secured a new $10 million unsecured line of credit from its Board C…
H.C. Wainwright initiated coverage of Galectin Therapeutics (NASDAQ:GALT), a $94.3 million market cap company, with a buy rating and a $6.00 price target on Tuesday. The stock has shown strong momentum with an 11% gain over the past week.…
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will…
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Signific…
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year…
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three…
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three…
Pharmacokinetics and safety of belapectin in patients with hepatic insufficiencyLack of impact of belapectin on cardiac repolarization (QT interval)Very High Elevation of Gamma-Glutamyl Transpeptidase (GGT) as a new marker of disease progr…
NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th A…
NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve o…
NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (…
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target…
NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th…
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th…
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th Edition of the Paris…
NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three…
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substanti…
NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three…
Galectin Therapeutics Inc. NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a bus…